bio

Neuroplasticity in Parkinson's disease
Véronique Sgambato (Principal Investigator)


Email: veronique.sgambato@inserm.fr
Phone: (334) 37 91 12 49


Véronique Sgambato is a neurobiologist (Researcher ID: G-9062-2017; ORCID: 0000-0002-8792-8586). She obtained her PhD in Neuroscience in 1998 from the University Pierre et Marie Curie in Paris (Ph.D. director Prof. Jean-Michel Deniau; Laboratory of Neuroanatomy and Neurochemistry headed by Prof. Marie-Jo Besson). After two postdoctoral trainings in the USA in the laboratories of Prof. Steven E. Hyman (Molecular Plasticity Section, NINDS, NIH, Bethesda, MD) and of Prof. Paul Greengard (Nobel Prize in Medicine in 2000; Laboratory of Molecular and Cellular Neuroscience, Rockefeller University, New-York City), she got an academic position in 2002 as a research scientist at INSERM, the French National Institute of Health and Medical Research. From 2003 to 2008, she worked in Grenoble (laboratories of Prof. Alim-Louis Benabid, INSERM U318 Preclinical Neuroscience and then of Dr. Marc Savasta, Grenoble Institute of Neuroscience) to investigate the impact of deep brain stimulation and levodopa treatment, the two major symptomatic treatments for Parkinson’s disease (PD), on the plasticity of basal ganglia neurons by combining behavioral, biochemical and immunohistochemical approaches on rodent models. In 2009, she moved to Lyon to join the Institute of cognitive Sciences Marc Jeannerod (Mixt Research Unit 5229 from the Scientific Research National Center (CNRS) and University of Lyon 1) and focused her research on the role of the serotonergic system in the pathophysiology of motor and non-motor symptoms in PD by combining behavioral, imaging and anatomical approaches on primates. Since January 1st, 2021, she leads a research team entitled “Neuroplasticity in Parkinson’s disease” with preclinical and clinical axes. Dr Sgambato was President of the French basal ganglia club from june 2018 to january 2023. She was a member of scientific committee of France Parkinson and of the Parkinson committee of Fondation de France for 6 years and is actually associate editor for Nature Journal of Parkinson's disease. Dr Sgambato’s work is supported by the CNRS, Université de Lyon, Fondation de France, Fondation Neurodis, France Parkinson and Agence Nationale de la Recherche.

Papers
  • R.Cirillo, S.Duperrier, P.Parekh, M.Millot, Q.Li, M.Thiolat, M.Morelli, J.Xie, D.Le Bars, J.Redouté, E.Bezard, V.Sgambato
    Striatal Serotonin 4 Receptor is Increased in Experimental Parkinsonism and Dyskinesia
    Journal of Parkinsons Disease, 261267, Vol: 14, (2024), doi: 10.3233/jpd-230331
  • Sgambato, Véronique
    The Serotonin 4 Receptor Subtype: A Target of Particular Interest, Especially for Brain Disorders
    International Journal of Molecular Sciences, 5245, Vol: 25, (2024), doi: 10.3390/ijms25105245
  • Sandra Duperrier, Analia Bortolozzi, Vèronique Sgambato
    Increased Expression of Alpha-, Beta-, and Gamma-Synucleins in Brainstem Regions of a Non-Human Primate Model of Parkinson's Disease
    International Journal of Molecular Sciences, 8586, Vol: 23, (2022), doi: 10.3390/ijms23158586
  • Cristina Miguelez, Philippe De Deurwaerdére, Vèronique Sgambato
    Editorial: Non-Dopaminergic Systems in Parkinson's Disease
    Frontiers in Pharmacology, Vol: 11, (2020), doi: 10.3389/fphar.2020.593822
  • Kathy Dujardin, Vèronique Sgambato
    Neuropsychiatric Disorders in Parkinson's Disease: What Do We Know About the Role of Dopaminergic and Non-dopaminergic Systems?
    Frontiers in Neuroscience, Vol: 14, (2020), doi: 10.3389/fnins.2020.00025
  • Mathilde Millot, Yosuke Saga, Sandra Duperrier, Elise Mètèreau, Maude Beaudoin-Gobert, Vèronique Sgambato
    Prior MDMA administration aggravates MPTP-induced Parkinsonism in macaque monkeys
    Neurobiology of Disease, 104643, Vol: 134, (2020), doi: 10.1016/j.nbd.2019.104643
  • Vèronique Sgambato
    Blood Flow as a Route for Bidirectional Propagation of Synucleinopathy in Parkinson's Disease?
    Movement Disorders, 1751--1751, Vol: 35, (2020), doi: 10.1002/mds.28236
  • Sgambato V.
    Breathing new life into neurotoxic-based monkey models of Parkinson's disease to study the complex biological interplay between serotonin and dopamine. In: 5-HT interaction with other neurotransmitters: experimental evidence and therapeutic relevance (Di Giovanni G and De Deurwaeredere P, Eds)
    Progress in Brain Research, (2020)
  • Maude Beaudoin-Gobert, Elise Mètèreau, Sandra Duperrier, Stèphane Thobois, Lèon Tremblay, Vèronique Sgambato
    Pathophysiology of levodopa-induced dyskinesia: Insights from multimodal imaging and immunohistochemistry in non-human primates
    NeuroImage, 132--141, Vol: 183, (2018), doi: 10.1016/j.neuroimage.2018.08.016
  • Stephane Thobois, Christine Brefel-Courbon, Didier Le Bars, Vèronique Sgambato-Faure
    Molecular Imaging of Opioid System in Idiopathic Parkinson's Disease
    275--303, (2018), doi: 10.1016/bs.irn.2018.07.029
  • Vèronique Sgambato, Lèon Tremblay
    Pathophysiology of dyskinesia and behavioral disorders in non-human primates: the role of serotonergic fibers
    Journal of Neural Transmission, 1145--1156, Vol: 125, (2018), doi: 10.1007/s00702-018-1871-7
  • Elise Mètèreau, Maude Beaudoin-Gobert, Sandra Duperrier, Stèphane Thobois, Lèon Tremblay, Vèronique Sgambato-Faure
    Diffusion tensor imaging marks dopaminergic and serotonergic lesions in the Parkinsonian monkey
    Movement Disorders, 298--309, Vol: 33, (2017), doi: 10.1002/mds.27201
  • Maude Beaudoin-Gobert, Justine Epinat, Elise Mètèreau, Sandra Duperrier, Sara Neumane, Bènèdicte Ballanger, Franck Lavenne, François Liger, Christian Tourvielle, Frèdèric Bonnefoi, Nicolas Costes, Didier Le Bars, Emmanuel Broussolle, Stèphane Thobois, Lèon Tremblay, Vèronique Sgambato-Faure
    Behavioural impact of a double dopaminergic and serotonergic lesion in the non-human primate
    Brain, 2632--2647, Vol: 138, (2015), doi: 10.1093/brain/awv183

Institut des Sciences Cognitives "Marc Jeannerod" | Copyright © 2019-2021